ReviewAnnals of nuclear medicine2026
PSMA-targeted radioligand therapy in prostate cancer: evidence hierarchy, platform maturity of ¹⁷⁷Lu-PSMA-617, and the clinical differentiation challenge for emerging radionuclides.
En Ting LinPubMed ↗Publisher ↗
No numbers read from the abstract.